Literature DB >> 24237244

Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus.

Thomas Neumann1, Lorenz C Hofbauer, Martina Rauner, Sabine Lodes, Bettina Kästner, Sybille Franke, Michael Kiehntopf, Thomas Lehmann, Ulrich A Müller, Gunter Wolf, Christine Hamann, Alexander Sämann.   

Abstract

AIM: Type 1 diabetes mellitus (T1DM) increases fragility fractures due to low bone mass, micro-architectural alterations and decreased bone formation. Sclerostin is expressed by osteocytes and inhibits osteoblastic bone formation. We evaluated serum sclerostin levels in T1DM and their association with bone mineral density (BMD), bone turnover, glycaemic control and physical activity. PATIENTS AND METHODS: In a cross-sectional study, 128 men and premenopausal women with long-standing T1DM (mean age 43·4 ± 8·8 years, diabetes duration 22·4 ± 9·5 years) and 77 age-, BMI (Body Mass Index) and gender-matched healthy individuals were evaluated.
RESULTS: Serum sclerostin levels were higher in T1DM compared with controls, irrespective of gender (male 0·55 ± 0·17 vs 0·49 ± 0·12 ng/ml, P = 0·046; female 0·52 ± 0·19 ng/ml vs 0·43 ± 0·12 ng/ml, P = 0·012). Partial correlation analysis adjusted for age and gender revealed a positive correlation between serum sclerostin levels and BMD at lumbar spine and femoral neck in T1DM and between BMD at lumbar spine, femoral neck and total hip in controls. Bone turnover markers, parathyroid hormone, calcium and vitamin D did not correlate with serum sclerostin levels in T1DM or controls. Physical activity was not associated with serum sclerostin levels. A multivariate analysis revealed that only the interaction of T1DM and age affects serum sclerostin levels but not T1DM alone. The influence of age on serum sclerostin levels was more pronounced in T1DM compared with controls.
CONCLUSIONS: Sclerostin serum levels were increased in patients with T1DM, and the positive correlation of age with serum sclerostin levels was stronger in T1DM. There was no effect of serum sclerostin levels on markers of bone metabolism and they do not explain the detrimental effects of T1DM on BMD.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24237244     DOI: 10.1111/cen.12364

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

Review 1.  Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts.

Authors:  Evangelia Kalaitzoglou; Iuliana Popescu; R Clay Bunn; John L Fowlkes; Kathryn M Thrailkill
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

Review 2.  Epidemiology of Skeletal Health in Type 1 Diabetes.

Authors:  David R Weber; George Schwartz
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

Review 3.  Skeletal growth and bone mineral acquisition in type 1 diabetic children; abnormalities of the GH/IGF-1 axis.

Authors:  Manish Raisingani; Brar Preneet; Brenda Kohn; Shoshana Yakar
Journal:  Growth Horm IGF Res       Date:  2017-04-28       Impact factor: 2.372

Review 4.  Effects of diabetes on osteocytes.

Authors:  Japneet Kaur; Sundeep Khosla; Joshua N Farr
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2022-06-24       Impact factor: 3.626

5.  Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes.

Authors:  Mishaela R Rubin; Ian H de Boer; Jye-Yu C Backlund; Valerie Arends; Rose Gubitosi-Klug; Amisha Wallia; Naina Sinha Gregory; Annette Barnie; Andrew J Burghardt; John M Lachin; Barbara H Braffett; Ann V Schwartz
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

Review 6.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

7.  An update on the role of RANKL-RANK/osteoprotegerin and WNT-ß-catenin signaling pathways in pediatric diseases.

Authors:  Giacomina Brunetti; Gabriele D'Amato; Mariangela Chiarito; Apollonia Tullo; Graziana Colaianni; Silvia Colucci; Maria Grano; Maria Felicia Faienza
Journal:  World J Pediatr       Date:  2018-10-20       Impact factor: 2.764

8.  Hyperglycemia increases the expression levels of sclerostin in a reactive oxygen species- and tumor necrosis factor-alpha-dependent manner.

Authors:  Jiho Kang; Kanitsak Boonanantanasarn; Kyunghwa Baek; Kyung Mi Woo; Hyun-Mo Ryoo; Jeong-Hwa Baek; Gwan-Shik Kim
Journal:  J Periodontal Implant Sci       Date:  2015-06-08       Impact factor: 2.614

9.  Inhibition of apoptosis signal-regulating kinase 1 enhances endochondral bone formation by increasing chondrocyte survival.

Authors:  G J Eaton; Q-S Zhang; C Diallo; A Matsuzawa; H Ichijo; M J Steinbeck; T A Freeman
Journal:  Cell Death Dis       Date:  2014-11-13       Impact factor: 8.469

Review 10.  Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype.

Authors:  Tayyab S Khan; Lisa-Ann Fraser
Journal:  J Osteoporos       Date:  2015-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.